Validating a self-report measure of HIV viral suppression: An analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study

被引：28
作者：
Carter A. [1 ,2 ]
De Pokomandy A. [3 ,4 ]
Loutfy M. [5 ,6 ]
Ding E. [2 ]
Sereda P. [2 ]
Webster K. [1 ]
Nicholson V. [1 ]
Beaver K. [5 ]
Hogg R.S. [1 ,2 ]
Kaida A. [1 ]
机构：
[1] Faculty of Health Sciences, Simon Fraser University, Burnaby, BC
[2] Epidemiology and Population Health Program, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC
[3] Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC
[4] Department of Family Medicine, McGill University, Montreal, QC
[5] Women's College Research Institute, Women's College Hospital, Toronto, ON
[6] Faculty of Medicine, University of Toronto, Toronto, ON
来源：
BMC Research Notes | / 10卷 / 1期
基金：
加拿大健康研究院;
关键词：
Canada; CHIWOS; HIV; Validation; Viral suppression; Women;
D O I：
10.1186/s13104-017-2453-8
中图分类号：
学科分类号：
摘要：
Background: We assessed the validity of a self-report measure of undetectable viral load (VL) among women with HIV in British Columbia (BC), Canada. Questionnaire data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study was linked with population-based clinical data from the BC Centre for Excellence in HIV/AIDS. Self-reported undetectable VL was assessed by the question: "What was your most recent VL, undetectable (i.e. <50 copies/mL) or detectable (i.e. ≥50 copies/mL)?" Laboratory measurements of VL <50 copies/mL (closest to/before study visit) were the criterion for validity analyses. We measured positive and negative predictive values (PPV, NPV) and likelihood ratios (LR+, LR-). Results: Of 356 participants, 99% were linked to clinical data. Those unlinked (n = 1), missing self-report VL (n = 18), or missing self-report and laboratory VL (n = 1) were excluded. Among the remaining 336: median age was 44 (IQR 37-51); 96% identified as cis-gender; 84% identified as heterosexual; and 45% identified as Indigenous, 40% White, 8% African, Caribbean, or Black, and 8% other/multiple ethnicities. Overall, 85% self-reported having an undetectable VL while 82% had clinical data indicating viral suppression. The PPV was 93.7 (95% CI 90.2-96.2) indicating that 94% of women who self-reported being undetectable truly were. The NPV was 80.4 (95% CI 66.9-90.2). LR+ was 3.2 (2.1-4.6) and LR- was 0.05 (0.03-0.10). Conclusions: Our self-report measure assessing undetectable VL strongly predicted true viral suppression among Canadian women with HIV. This measure can be used in research settings without laboratory data in regions with high rates of VL testing and suppression. © 2017 The Author(s).
引用
收藏
相关论文
共 23 条
  • [1] Gunthard H.F., Saag M.S., Benson C.A., Del Rio C., Eron J.J., Gallant J.E., Et al., Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel, JAMA, 316, 2, pp. 191-210, (2016)
  • [2] Initiation of antiretroviral therapy in early asymptomatic HIV infection, N Engl J Med, 2015, 373, pp. 795-807, (2015)
  • [3] Temprano A.N.R.S., A trial of early antiretrovirals and isoniazid preventive therapy in Africa, N Engl J Med, 2015, 373, pp. 808-822, (2015)
  • [4] Hogg R.S., Heath K.V., Yip B., Craib K.J., O'Shaughnessy M.V., Schechter M.T., Et al., Improved survival among HIV-infected individuals following initiation of antiretroviral therapy, JAMA, 279, 6, pp. 450-454, (1998)
  • [5] Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., Et al., Prevention of HIV-1 infection with early antiretroviral therapy, N Engl J Med, 365, 6, pp. 493-505, (2011)
  • [6] Montaner J.S., Treatment as prevention - A double hat-trick, Lancet, 378, 9787, pp. 208-209, (2011)
  • [7] Montaner J.S., Lima V.D., Harrigan P.R., Lourenco L., Yip B., Nosyk B., Et al., Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The "HIV Treatment as Prevention" experience in a Canadian setting, PLoS ONE, 9, 2, (2014)
  • [8] Rodger A., Bruun T., Cambiano V., Vernazza P., Estrada V., Van Lunzen J., Et al., 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), (2014)
  • [9] Rodger A., Association between sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy: The PARTNER study, 21st International AIDS Conference, (2016)
  • [10] Lourenco L., Lima V.D., Heath K., Nosyk B., Gilbert M., Colley G., Et al., Process monitoring of an HIV treatment as prevention program in British Columbia, Canada, JAIDS J Acquir Immune Defic Syndr, 67, 3, pp. e94-e109, (2014)
123